- Sponsor of the Heart of Genetic Counseling
program and award, recognizing excellence in patient care -
- These studies combined with new digital tools
aim to increase access and frequency of hereditary cancer screening
both before and during treatment -
SAN
FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Researchers
from Invitae (NYSE: NVTA), a leading medical genetics company, are
showcasing their work next week at the National Society of Genetic
Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of
genetics-informed patient care. In addition to its research
presentations, the company will present the Heart of Genetic
Counseling Award which recognizes excellence in the field of
genetic counseling.
The company's research presentations, which include a sponsored
session, oral presentations and posters, present data on
improvements in classifying Variants of Uncertain Significance
(VUS), how using digital tools can increase hereditary cancer
screening access and other topics related to the field of medical
genomics. The sponsored session will focus on the ever-evolving
field of genetic counseling and the tools needed to navigate change
through an interactive workshop using the odyssey planning
framework.
"The NSGC Annual Conference is a great opportunity for Invitae
researchers to share cutting-edge scientific advancements with
genetic counselors who play an integral role in genetics-informed
patient care," said Robert Nussbaum,
M.D., chief medical officer at Invitae. "It also gives us a chance
to show our continued commitment to genetic counselors and their
patients by awarding the Heart of Genetic Counseling Award to a
genetic counselor who was nominated by a patient for extraordinary
care and compassion."
Heart of Genetic Counseling Award
Invitae joins NSGC in presenting the Heart of Genetic Counseling
Award – honoring excellence in genetic counseling and patient care
as recognized by patients. The nominations include patient stories
that highlight the significant clinical and personal impact their
genetic counselor had on their lives and the lives of their
families. This year's award will be presented during the ceremony
on Wednesday, October 18, at
7 p.m. CT. Among several nominations,
the finalists are:
Leslie Walsh Cyprych MS, MPH, CGC, Children's Hospital of
Pittsburgh, was nominated by a
mother for providing unwavering patient advocacy, support and
compassion after her daughter was diagnosed with Aicardi-Goutieres
syndrome (AGS), a rare, progressive, and incurable genetic disease.
Cyprych has continuously gone above and beyond to coordinate the
daughter's care, help navigate the healthcare system, and to
provide information and meaningful emotional support.
Andrea Gainey MS, LCGC, UConn Health Huntington's Disease
Program, provided crucial care, comfort and guidance to a family
facing Huntington's Disease (HD). Gainey understands the stigma
that surrounds HD and how difficult the decision to test is and
helped establish free anonymous testing and confidential lab
reports. Considered a leader in the HD community, Gainey has helped
generations of families deal with this devastating disease on a
daily basis.
Victoria Suslovitch MS, CGC, Ambry Genetics, formerly
with Boston Children's Hospital, was nominated for offering
compassion, emotional support and guidance to a family whose son is
affected by a devastating rare genetic disease, called KCNQ2
developmental epileptic encephalopathy. Suslovitch was a guiding
light helping each family member deal with their frightening
medical journey. Suslovitch drew on her personal experience to
connect with siblings as both a peer and professional and taught
healthy coping mechanisms.
The Heart of Genetic Counseling Award will be presented on
Wednesday, October 18, from
7 p.m. to 9 p.m. CT.
Full presentation schedule
Invitae continues to demonstrate scientific innovation and
excellence as supported by the number of accepted sessions,
presentations, and posters. The full schedule of Invitae
presentations and posters at the conference can be found on our
website.
Wednesday, October 18
- Poster CAN65. Cascade testing with comprehensive
multigene panels for hereditary cancer identifies unexpected
findings in relatives. | Presented by: Brandie Heald, M.S., C.G.C., Invitae. |
5:30 p.m. – 7
p.m. CT
- Poster CAN75. One of these is not like the others: a
descriptive study of the attenuated phenotype of PMS2 | Presented
by: Brandie Heald, M.S., C.G.C.,
Invitae. | 5:30 p.m – 7 p.m. CT
- Poster CAN67. Patient uptake of physician
recommendations following prostate cancer germline genetic testing.
| Presented by: Sarah M. Nielsen,
Invitae. | 5:30 p.m. – 7 p.m. CT
- Heart of Genetic Counseling Award Presentation |
Presented by: Invitae and NSGC. | 7
p.m. – 9 p.m. CT
Thursday, October 19
- Educational Breakout Session C03. Increasing access
to hereditary cancer screening: emerging evidence on the use of
digital tools for ascertainment of individuals at risk and
considerations for care delivery. | Presented by: Shivani Nazareth,
M.S., C.G.C., Wendy Kohlmann, M.S.,
C.G.C., Vera Cherepakho, L.C.G.C., Meredith
Gerhart, M.S., C.G.C., Sarah
Knerr, Ph.D., Catharine Wang,
Ph.D., Rebecca Carr, M.S., C.G.C.,
Colleen Caleshu, M.S., C.G.C.,
Sarah Savage, M.S., C.G.C. |
11 a.m. – 12:30 p.m. CT
- Sponsored session. Charting your genetic counseling
odyssey: Navigating with purpose and vision. | Presented by:
Jennifer Young, Ph.D., Feinberg
School of Medicine Northwestern
University, and Ana Morales,
M.S., C.G.C., Invitae. | 12:45 p.m. –
2 p.m. CT
- Poster CAN64. The estimated healthcare spend to identify
one hereditary cancer syndrome patient with a deep intronic
pathogenic variant by RNA sequencing is nearly 500x more costly
than identifying one patient with multi-gene panel DNA testing. |
Presented by: Brandie Heald, M.S.,
C.G.C., Invitae. | 4:30 p.m. –
6:30 p.m. CT
- Poster GGT218. Minimizing uncertainty and increasing
equity in genetic testing: the role of machine learning tools in
the classification of genetic variants. | Presented by:
Flavia M. Facio, M.S., C.G.C..
Invitae. | 4:30 p.m. – 6:30 p.m. CT
- Poster GGT282: Utilization of an Automated,
Probability-Based Algorithm to Determine Pharmacogenomic Adverse
Drug Outcome Risk in Cancer Patients. | Presented by: Sienna
Aguilar, M.S., L.C.G.C., Invitae. | 4:30-6:30 p.m.
- Poster GGT256. Positive yield of reproductive
carrier screening in the context of revised ACMG recommendations
for tiered carrier screening. | Presented by: Dana Neitzel, M.S., C.G.C., Invitae. |
4:30-6:30 p.m. CT
- Oral Presentation B16. User Testing of a Pre-Visit
Chatbot Developed for Population Genomic Screening and Counseling.
| Presented by: Kelly Morgan, M.S.,
C.G.C. | 4:45-5:45 p.m. CT
- Oral Presentation B17. Yield of integrated DNA and
RNA analysis of hereditary cancer associated genes based on cancer
diagnosis. | Presented by: Brandie
Heald, M.S., C.G.C., Invitae. | 4:45
- 5:45 p.m. CT
Friday, October 20
- Oral Presentation C14. A Pilot Study Comparing
the Effectiveness of Pre-test Genetic Counseling Using a Chatbot
versus Traditional In-person Genetic Counseling in Women Newly
Diagnosed with Breast Cancer. | Presented by: Ryan Noss, M.S., C.G.C. | 10:15 a.m. - 11:15 a.m. CT
On-demand session
- Advancing Variant Classification: Steps in Reducing Uncertainty
and Improving Patient Outcomes. | Presented by: Heidi Rehm,
Ph.D., Yuya Kobayashi, Ph.D.,
Jason Carmichael, M.S., C.G.C.,
Sayoni Lahiri, C.G.C., Flavia M. Facio
C.G.C. | Available in the live stream and on-demand
portions of the program via NSGC conference app.
To learn more about Invitae's presence at the NSGC 42nd Annual
Conference or the Heart of Genetic Counseling Award, visit our
website.
About Invitae
Invitae (NYSE: NVTA)
is a leading medical genetics company trusted by millions of
patients and their providers to deliver timely genetic information
using digital technology. We aim to provide accurate and actionable
answers to strengthen medical decision-making for individuals and
their families. Invitae's genetics experts apply a
rigorous approach to data and research, serving as the foundation
of their mission to bring comprehensive genetic information into
mainstream medicine to improve healthcare for billions of
people.
To learn more, visit invitae.com and follow for updates on
Twitter, Instagram,
Facebook and LinkedIn @Invitae.
Safe Harbor Statement
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the content of the company's research
presentations and posters; the objectives of the company's studies
and tools; and the company's beliefs regarding the quality and
impact of its research. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the company's ability to grow its
business in a cost-efficient manner; the company's history of
losses; the company's ability to maintain important customer
relationships; the company's ability to compete; the company's need
to scale its infrastructure in advance of demand for its tests and
to increase demand for its tests; the risk that the company may not
obtain or maintain sufficient levels of reimbursement for its
tests; the applicability of clinical results to actual outcomes;
the company's ability to use rapidly changing genetic data to
interpret test results accurately and consistently; risks
associated with litigation; security breaches, loss of data and
other disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2023. These
forward-looking statements speak only as of the date hereof,
and Invitae Corporation disclaims any obligation to
update these forward-looking statements.
Contact:
Amanda McQuery
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-to-present-data-at-the-national-society-of-genetic-counselors-42nd-annual-conference-that-supports-advancements-in-medical-genomics-301952554.html
SOURCE Invitae Corporation